Videos

Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL

 

Arnon P. Kater, MD, PhD, Professor of Hematology, Amsterdam University Medical Center, the Netherlands, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax monotherapy in patients with relapsed/refractory CLL. These results were presented at the virtual 2020 EHA Annual Congress.

3 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Stay in the know.
OncNet Newsletter